| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
50,777 |
35,245 |
$2.46M |
| 99199 |
Unlisted special service, procedure or report |
279,906 |
162,866 |
$1.65M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
24,077 |
16,216 |
$1.65M |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
9,051 |
5,498 |
$781K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
4,584 |
2,508 |
$599K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
7,160 |
5,228 |
$489K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
6,733 |
4,814 |
$448K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
5,828 |
4,128 |
$408K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
6,084 |
4,050 |
$388K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
18,007 |
12,194 |
$258K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
9,652 |
6,671 |
$224K |
| 99401 |
|
7,984 |
5,131 |
$188K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
17,970 |
12,779 |
$112K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,208 |
2,403 |
$101K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
9,213 |
6,878 |
$96K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
2,597 |
2,125 |
$71K |
| D0145 |
Oral evaluation for a patient under three years of age |
2,001 |
1,307 |
$50K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
4,981 |
1,838 |
$49K |
| 99058 |
|
2,744 |
2,133 |
$36K |
| 96127 |
|
10,391 |
7,231 |
$33K |
| 92551 |
|
16,850 |
12,145 |
$23K |
| D1206 |
Topical application of fluoride varnish |
1,970 |
1,294 |
$22K |
| 90651 |
|
2,675 |
1,836 |
$21K |
| 99381 |
|
276 |
232 |
$21K |
| 99421 |
|
972 |
516 |
$20K |
| 99050 |
|
952 |
741 |
$19K |
| 90734 |
|
2,237 |
1,427 |
$15K |
| 99070 |
|
2,608 |
1,701 |
$13K |
| 90474 |
|
891 |
537 |
$12K |
| 99441 |
|
531 |
340 |
$12K |
| 80061 |
Lipid panel |
1,062 |
645 |
$12K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
301 |
173 |
$7K |
| 99173 |
|
14,934 |
10,792 |
$7K |
| 99239 |
Hospital discharge day management, more than 30 minutes |
79 |
66 |
$6K |
| 0071A |
|
117 |
84 |
$4K |
| 99051 |
|
187 |
161 |
$4K |
| 81002 |
|
1,889 |
1,254 |
$3K |
| 82947 |
|
1,084 |
652 |
$3K |
| 69210 |
|
135 |
76 |
$3K |
| 83655 |
|
290 |
182 |
$2K |
| 90715 |
|
1,541 |
984 |
$2K |
| 90461 |
|
749 |
602 |
$2K |
| 96161 |
|
926 |
493 |
$1K |
| 0072A |
|
31 |
23 |
$1K |
| 87807 |
|
152 |
90 |
$1K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
48 |
19 |
$1K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
166 |
88 |
$1K |
| 99177 |
|
2,464 |
1,843 |
$903.06 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
13 |
13 |
$792.22 |
| 99460 |
|
16 |
12 |
$766.08 |
| 99442 |
|
13 |
12 |
$732.24 |
| 81025 |
|
157 |
88 |
$687.18 |
| 85018 |
|
933 |
528 |
$633.67 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
48 |
19 |
$575.00 |
| 90619 |
|
263 |
180 |
$526.47 |
| 90686 |
|
960 |
676 |
$518.88 |
| 90473 |
|
47 |
34 |
$421.47 |
| 90633 |
|
2,591 |
1,829 |
$375.28 |
| 90621 |
|
202 |
150 |
$370.01 |
| 90716 |
|
973 |
709 |
$244.00 |
| 2001F |
|
9,127 |
7,403 |
$243.45 |
| 94760 |
|
1,757 |
1,138 |
$230.34 |
| 90656 |
|
2,527 |
1,590 |
$132.64 |
| 90707 |
|
885 |
641 |
$79.73 |
| 90698 |
|
3,589 |
2,435 |
$61.00 |
| 90696 |
|
928 |
672 |
$58.02 |
| 99188 |
|
28 |
26 |
$45.30 |
| 90713 |
|
113 |
107 |
$32.15 |
| 90680 |
|
2,271 |
1,578 |
$15.00 |
| 90670 |
|
4,195 |
2,946 |
$4.00 |
| 90710 |
|
953 |
693 |
$3.00 |
| 90744 |
|
2,093 |
1,477 |
$1.00 |
| 1160F |
|
9,186 |
7,365 |
$0.00 |
| 90655 |
|
325 |
228 |
$0.00 |
| 90700 |
|
516 |
479 |
$0.00 |
| 3078F |
|
3,873 |
3,292 |
$0.00 |
| 90658 |
|
188 |
117 |
$0.00 |
| 90649 |
|
15 |
12 |
$0.00 |
| G9920 |
Screening performed and negative |
87 |
74 |
$0.00 |
| 99072 |
|
99 |
27 |
$0.00 |
| 3008F |
|
4,242 |
3,608 |
$0.00 |
| 3074F |
|
4,057 |
3,453 |
$0.00 |
| 90647 |
|
456 |
424 |
$0.00 |
| 99000 |
|
176 |
134 |
$0.00 |
| 36416 |
|
275 |
149 |
$0.00 |
| 91307 |
|
160 |
116 |
$0.00 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
35 |
14 |
$0.00 |
| 90660 |
|
90 |
49 |
$0.00 |
| 90620 |
|
18 |
16 |
$0.00 |